MB-102 is a Gene-Modified Cell Therapy owned by Mustang Bio, and is involved in 3 clinical trials, which are ongoing.

MB-102 elicits immunostimulant effects. Interleukin-3 receptor alpha chain (CD123) is over expressed in cancers. The therapy by expressing chimeric antigen receptors redirects the T-cells to acute myeloid leukemia-associated antigens which recognize CD123 cells and destroy them.

The revenue for MB-102 is expected to reach a total of $88m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the MB-102 NPV Report.

MB-102 was originated by City of Hope and is currently owned by Mustang Bio.

MB-102 Overview

MB-102 is under development for the treatment of relapsed or refractory acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm (natural killer cell lymphomas). The therapy is administered through intravenous route. It includes autologous T cells genetically modified to express CD123 specific hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor which targets different epitopes on CD123. The drug candidate was under development for high-risk myelodysplastic syndrome (MDS) and 

Mustang Bio Overview

Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.

The operating loss of the company was US$66.7 million in FY2021, compared to an operating loss of US$56.8 million in FY2020. The net loss of the company was US$66.4 million in FY2021, compared to a net loss of US$60 million in FY2020.

Quick View – MB-102

Report Segments
  • Innovator
Drug Name
  • MB-102
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.